Overview

A Study to Investigate the Effects of PF00610335 on the QT/QTC Interval in Healthy Volunteers

Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
A study to determine the cardiovascular effects of PF00610335 in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Fluoroquinolones
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination